Waclaw Szybalski's contribution to immunotherapy: HGPRT mutation & HAT selection as first steps to gene therapy and hybrid techniques in mammalian cells.
Gene
; 525(2): 158-61, 2013 Aug 10.
Article
en En
| MEDLINE
| ID: mdl-23562724
ABSTRACT
In this report we describe Waclaw Szybalski's fundamental contribution to gene therapy and immunotherapy. His 1962 PNAS paper (Szybalska and Szybalski, 1962) documented the first successful gene repair in mammalian cells. Furthermore, this was also the first report on the HAT selection method used later in many applications. Most importantly, somatic cell fusion and HAT selection were subsequently used to develop monoclonal antibody technology, which contributed significantly to the progress of today's medicine.
Palabras clave
ADA-SCID; DNAse; ES cells; Gene therapy; Genetic transformation; HAT; HAT selection; HPRT; IMP; Monoclonal antibodies; RT-PCR; Waclaw Szybalski; adenosine deaminase-deficient severe combined immunodeficiency; deoxyribonuclease; embryonic stem cells; hypoxanthine, aminopterin, thymidine; hypoxanthine-guanine phosphoribosyl transferase; inosine monophosphate; reverse transcription polymerase chain reaction
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Terapia Genética
/
Hipoxantina Fosforribosiltransferasa
/
Inmunoterapia
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Gene
Año:
2013
Tipo del documento:
Article
País de afiliación:
Polonia